Safety of RG2077 in Patients With Multiple Sclerosis
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
Multiple sclerosis (MS) is an autoimmune disorder. In this disease, the body's immune system
attacks and destroys the cells that cover and protect nerves. This study will test the safety
of a new drug called RG2077 that is designed to treat MS. The study will not determine
whether RG2077 is effective in treating MS, only whether it is safe to use in patients with
MS.
Study hypothesis: RG2077 will arrest MS if administered early in the course of MS and
decrease accumulation of lesions on MRI.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)